{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:23:24Z","timestamp":1788319404051,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04490-4","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T07:12:32Z","timestamp":1756105952000},"page":"2417-2425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Shuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"7","key":"4490_CR1","doi-asserted-by":"publisher","first-page":"e0305870","DOI":"10.1371\/journal.pone.0305870","volume":"19","author":"AM Affandi","year":"2024","unstructured":"Affandi AM, Thiruchelvam K (2024) Patient perspective on psoriasis: psychosocial burden of psoriasis and its management in Malaysia. PLoS One 19(7):e0305870. https:\/\/doi.org\/10.1371\/journal.pone.0305870","journal-title":"PLoS One"},{"issue":"19","key":"4490_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"4","key":"4490_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I, Kasparek T, Frade S, Barrio SF, Augustin M (2023) Patient perspectives on psoriatic disease burden: results from the global psoriasis and beyond survey. Dermatology 239(4):621\u2013634. https:\/\/doi.org\/10.1159\/000528945","journal-title":"Dermatology"},{"issue":"10","key":"4490_CR4","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, Warham R, Lambert J, Wiegratz S, Szilagyi B, Blauvelt A (2024) Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb) 14(10):2841\u20132857. https:\/\/doi.org\/10.1007\/s13555-024-01261-6","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"4490_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A (2020) Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol 19(5):487\u2013492","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"4490_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00403-022-02420-5","volume":"315","author":"ND Boswell","year":"2023","unstructured":"Boswell ND, Cook MK, Balogh EA, Feldman SR (2023) The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review. Arch Dermatol Res 315(4):699\u2013706. https:\/\/doi.org\/10.1007\/s00403-022-02420-5","journal-title":"Arch Dermatol Res"},{"issue":"24","key":"4490_CR7","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2024.4899","volume":"331","author":"DC Butler","year":"2024","unstructured":"Butler DC, Berger T, Elmariah S, Kim B, Chisolm S, Kwatra SG, Mollanazar N, Yosipovitch G (2024) Chronic pruritus: a review. JAMA 331(24):2114\u20132124. https:\/\/doi.org\/10.1001\/jama.2024.4899","journal-title":"JAMA"},{"key":"4490_CR8","unstructured":"Committee CMADaVBP (2023) Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chinese J Dermatol 56 (7):573\u2013625"},{"issue":"4","key":"4490_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s13555-024-01147-7","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A (2024) Sustained improvements in clinical and patient-reported outcomes and quality of life through 5 years among Ixekizumab-treated patients with complete clearance of scalp psoriasis by week 60. Dermatol Ther (Heidelb) 14(4):1007\u20131018. https:\/\/doi.org\/10.1007\/s13555-024-01147-7","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"4490_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/09546634.2015.1093589","volume":"27","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN (2016) Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat 27(3):224\u2013227. https:\/\/doi.org\/10.3109\/09546634.2015.1093589","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"4490_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210\u2013216. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"issue":"10281","key":"4490_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J (2021) Psoriasis. Lancet 397(10281):1301\u20131315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"key":"4490_CR13","doi-asserted-by":"publisher","unstructured":"Jankowiak B, Krajewska-Kulak E, Jakoniuk M, Khvorik DF (2023) Stigmatization among patients with plaque psoriasis. J Clin Med 12 (19). https:\/\/doi.org\/10.3390\/jcm12196425","DOI":"10.3390\/jcm12196425"},{"issue":"5","key":"4490_CR14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1159\/000531420","volume":"239","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Li Y, Huang D, Zhong X, Yu Q, Liang Y, Dang L, Lv C, Lin B, Zhang F, Liang Y, Lu J, Shi Y (2023) Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective real-world study. Dermatology 239(5):802\u2013810. https:\/\/doi.org\/10.1159\/000531420","journal-title":"Dermatology"},{"key":"4490_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914734","author":"A Kaczmarska","year":"2023","unstructured":"Kaczmarska A, Kwiatkowska D, Skrzypek KK, Kowalewski ZT, Jaworecka K, Reich A (2023) Pathomechanism of pruritus in psoriasis and atopic dermatitis: novel approaches, similarities and differences. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241914734","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4490_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s43440-020-00206-y","volume":"73","author":"S Kahremany","year":"2021","unstructured":"Kahremany S, Hofmann L, Harari M, Gruzman A, Cohen G (2021) Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacol Rep 73(2):443\u2013453. https:\/\/doi.org\/10.1007\/s43440-020-00206-y","journal-title":"Pharmacol Rep"},{"issue":"4","key":"4490_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ (2020) Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 182(4):840\u2013848. https:\/\/doi.org\/10.1111\/bjd.18245","journal-title":"Br J Dermatol"},{"issue":"2","key":"4490_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/09546634.2020.1772454","volume":"33","author":"NJ Korman","year":"2022","unstructured":"Korman NJ, Malatestinic W, Goldblum OM, Murage MJ, Renda L, Lin CY, Lucas J, Middleton C, Lobosco S (2022) Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient\u2019s perspective. J Dermatolog Treat 33(2):733\u2013739. https:\/\/doi.org\/10.1080\/09546634.2020.1772454","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"4490_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C (2023) Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III erasure and fixture trials. Br J Dermatol 188(2):198\u2013207. https:\/\/doi.org\/10.1093\/bjd\/ljac040","journal-title":"Br J Dermatol"},{"issue":"19","key":"4490_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","volume":"97","author":"NC Laucis","year":"2015","unstructured":"Laucis NC, Hays RD, Bhattacharyya T (2015) Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am 97(19):1628\u20131634. https:\/\/doi.org\/10.2106\/JBJS.O.00030","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"4490_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40257-019-00466-2","volume":"20","author":"MG Lebwohl","year":"2019","unstructured":"Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A (2019) Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with Brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol 20(6):863\u2013871. https:\/\/doi.org\/10.1007\/s40257-019-00466-2","journal-title":"Am J Clin Dermatol"},{"key":"4490_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Kim M (2023) Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241713313","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4490_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ad.2023.03.004","volume":"114","author":"FJ Navarro-Trivino","year":"2023","unstructured":"Navarro-Trivino FJ (2023) Pruritus in dermatology: Part 2 - diseases and their treatment. Actas Dermosifiliogr 114(7):613\u2013626. https:\/\/doi.org\/10.1016\/j.ad.2023.03.004","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"4490_CR24","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s13555-024-01245-6","volume":"14","author":"L Puig","year":"2024","unstructured":"Puig L, Costanzo A, de Jong E, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C (2024) Progression of quality of life in patients with plaque psoriasis who achieved three or more years of complete skin clearance with Guselkumab treatment: a post hoc analysis of the VOYAGE 1 clinical trial. Dermatol Ther (Heidelb) 14(9):2539\u20132558. https:\/\/doi.org\/10.1007\/s13555-024-01245-6","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"4490_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00403-008-0885-7","volume":"300","author":"K Reich","year":"2008","unstructured":"Reich K, Griffiths CE (2008) The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 300(10):537\u2013544. https:\/\/doi.org\/10.1007\/s00403-008-0885-7","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"4490_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jdv.18068","volume":"36","author":"K Reich","year":"2022","unstructured":"Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Kaplan Saday K, Warren RB (2022) Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. J Eur Acad Dermatol Venereol 36(8):1275\u20131283. https:\/\/doi.org\/10.1111\/jdv.18068","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4490_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12112","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C (2013) Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168(2):402\u2013411. https:\/\/doi.org\/10.1111\/bjd.12112","journal-title":"Br J Dermatol"},{"issue":"1","key":"4490_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jaad.2021.12.032","volume":"88","author":"C Ryan","year":"2023","unstructured":"Ryan C, Puig L, Zema C, Thompson EHZ, Yang M, Wu E, Bensimon A, Huang X, Joshi AD, Elewski B (2023) The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. J Am Acad Dermatol 88(1):169\u2013172. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.032","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4490_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S Stander","year":"2022","unstructured":"Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M (2022) Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol 36(4):573\u2013581. https:\/\/doi.org\/10.1111\/jdv.17870","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4490_CR30","doi-asserted-by":"publisher","unstructured":"Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P (2016) Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 75 (1):77\u201382 e77. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026","DOI":"10.1016\/j.jaad.2016.03.026"},{"issue":"1","key":"4490_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ejp.768","volume":"20","author":"JC Szepietowski","year":"2016","unstructured":"Szepietowski JC, Reich A (2016) Pruritus in psoriasis: an update. Eur J Pain 20(1):41\u201346. https:\/\/doi.org\/10.1002\/ejp.768","journal-title":"Eur J Pain"},{"issue":"4","key":"4490_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaad.2014.05.001","volume":"71","author":"J Takeshita","year":"2014","unstructured":"Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Gelfand JM (2014) Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 71(4):633\u2013641. https:\/\/doi.org\/10.1016\/j.jaad.2014.05.001","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4490_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Travaglini M, Costanzo A, Narcisi A (2024) Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb) 14(6):1649\u20131657. https:\/\/doi.org\/10.1007\/s13555-024-01182-4","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"4490_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, Klekotka P (2015) Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat 26(3):235\u2013239. https:\/\/doi.org\/10.3109\/09546634.2014.943687","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"4490_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J (2025) Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol 92(1):92\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.031","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4490_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","volume":"87","author":"C Zhang","year":"2022","unstructured":"Zhang C, Yan K, Diao Q, Guo Q, Jin H, Yang S, Chen X, Lei T, Wu J, Yu H, Zheng M, Gao X, Sinclair R, Zhu Y, Xu Q, Xu J (2022) A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 87(1):95\u2013102. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.005","journal-title":"J Am Acad Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04490-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:53:35Z","timestamp":1770882815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04490-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4490"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04490-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review boards of The Second Hospital of Jilin University approved this phase III trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This was a post-hoc analysis of a randomized, double-blind, parallel, placebo-controlled, multicenter phase III trial (NCT04839016) conducted from April 2021 through March 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}